Back to Search

A Phase I/Ib, Open-label, Multi-center Study of DFF332 as a Single Agent and in Combination With Everolimus or IO Agents in Patients With Advanced/Relapsed ccRCC and Other Malignancies With HIF2? Stabilizing Mutations

  • Protocol Number: 202111014
  • Principal Investigator: Picus, Joel
  • Cancer Types: GU: Bladder, Kidney, Prostate, Testicular

For more information on this trial, contact us here:


Brief Summary

Protocol Interventions